mRNA is an exciting new class of drug that has the potential to play a role in gene therapy. With several advantages over DNA, including the lack of any requirement for nuclear localization or transcription and the nearly negligible possibility of genomic integration of the delivered sequence, mRNA holds tremendous potential to cure diseases. However, the labile nature of mRNA is an important limitation to its in vivo application. Thus, its paramount to develop mRNA delivery strategies for its success as a therapeutic. In this presentation, drug delivery platforms will be discussed, with focus on commercial application and viability.